Results 11 to 20 of about 144,316 (318)

Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. [PDF]

PLoS ONE, 2010
Erythropoietin is a growth factor commonly used to manage anemia in patients with chronic kidney disease. A significant clinical challenge is relative resistance to erythropoietin, which leads to use of successively higher erythropoietin doses, failure ...
Eliyahu V Khankin, Walter P Mutter, Hector Tamez, Hai-Tao Yuan, S Ananth Karumanchi, Ravi Thadhani   +5 more
doaj   +1 more source

Serum Erythropoietin in Patients with Chronic Renal Failure in the Predialysis Stage [PDF]

Journal of Biomedical & Clinical Research, 2023
A prospective study was carried out of serum erythropoietin levels in patients with chronic renal failure/chronic kidney disease in the predialysis period. The study is part of scientific project № 2/2022, financed by Medical University-Pleven.
Adelaida Ruseva, Gergana Todorova, Aygulya Akisheva, Diana Pendicheva-Duhlenska, Vasil Todorov, Milena Stoimenova   +5 more
doaj   +3 more sources

Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men [PDF]

, 2013
<p>Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hbmass) and maximal oxygen uptake (v˙ O2 max).</p> <p>Purpose: This study defined the time course of changes in Hbmass, v˙ O2 max as well as running time trial ...
A Lucia, AJ Brien, B Berglund, BD Levine, C Ahlgrim, C Lundby, C Lundby, C Lundby, CC Chang, CP Alfrey, D Boning, Diresibachew H. Wondimu, DL Costill, DP Wilkerson, Elias T. Zambidis, Evangelia Daskalaki, G Banfi, G Ninot, G Russell, GP Millet, H Ehrenreich, I Mujika, JD Belcher, JJ Thomsen, JM Kirkeberg, John D. McClure, Jérôme Durussel, K Heinicke, K Miskowiak, KI Birkeland, L Rice, L Rice, M Audran, M Brines, Martin Anderson, Neal Padmanabhan, NV Olsen, P Connes, P Rasmussen, PB Laursen, R Parisotto, Rajan K. Patel, RJ Shephard, RR Engel, RS Franco, SW Ryter, TD Noakes, TD Noakes, Tushar Chatterji, W Jelkmann, W Schmidt, Yannis P. Pitsiladis   +51 more
core   +7 more sources

Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care [PDF]

, 2012
Author can archive publisher's pdf. Free via Creative Commons: CC-BENCHTOBEDSIDE-2.0.
Nandra, KK, Patel, NSA, Thiemermann, C
core   +1 more source

Age-dependent expression of the erythropoietin gene in rat liver and kidneys [PDF]

, 1992
Using RNAse protection, we have made quantitative measurements of erythropoietin (EPO) mRNA in liver and kidneys of developing rats (days 1-54), to determine the relative contribution of both organs to the total EPO mRNA, to monitor changes which occur ...
Bauer, Christian, Eckardt, Kai-Uwe, Kurtz, Armin, Ratcliffe, P. J., Tan, C. C.   +4 more
core   +2 more sources

Prognostic significance of endogenous erythropoietin in long-term outcome of patients with acute decompensated heart failure [PDF]

, 2016
Aims Although previous reports suggest that an elevated endogenous erythropoietin (EPO) level is associated with worse clinical outcomes in chronic heart failure (HF) patients, the prognostic implication of EPO in patients with acute decompensated HF ...
Anand, Anker, Asaumi, Beguin, Belonje, Belonje, Belonje, Breunig, Cazzola, Diskin, Ezekowitz, Feldschuh, George, Ghali, Grote Beverborg, Levy, Lipsic, Massie, McKee, Meer, Meer, Meer, Silverberg, Smilde, Swedberg, Takei, Teerlink, Westenbrink   +27 more
core   +1 more source

New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis

Haematologica, 2018
Primary familial and congenital polycythemia is characterized by erythropoietin hypersensitivity of erythroid progenitors due to germline nonsense or frameshift mutations in the erythropoietin receptor gene.
Florence Pasquier, Caroline Marty, Thomas Balligand, Frédérique Verdier, Sarah Grosjean, Vitalina Gryshkova, Hana Raslova, Stefan N. Constantinescu, Nicole Casadevall, William Vainchenker, Christine Bellanné-Chantelot, Isabelle Plo   +11 more
doaj   +1 more source

The use of genes for performance enhancement: doping or therapy? [PDF]

, 2011
Recent biotechnological advances have permitted the manipulation of genetic sequences to treat several diseases in a process called gene therapy. However, the advance of gene therapy has opened the door to the possibility of using genetic manipulation ...
Collares, T. F., Collares, T. V., Oliveira, R. S., Seixas, F. K., Smith, Kevin R.   +4 more
core   +5 more sources

Macrophages as novel target cells for erythropoietin

Haematologica, 2010
Background Our original demonstration of immunomodulatory effects of erythropoietin in multiple myeloma led us to the search for the cells in the immune system that are direct targets for erythropoietin.
Lilach Lifshitz, Galit Tabak, Max Gassmann, Moshe Mittelman, Drorit Neumann   +4 more
doaj   +1 more source

Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure [PDF]

, 1993
The single-dose pharmacokinetics of recombinant human erythropoietin (rHuEPO) given SC was investigated in 20 patients aged 7-20 years at different stages of chronic renal failure.
Braun, A., Ding, R., Fies, T., Kurtz, Armin, Schärer, K., Seidel, C.   +5 more
core   +1 more source